Clinical trial · Observational
MRI Features in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer
Risk Criteria Based on MRI Features Outperform Radiographic TNM Staging in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer:A Single-Center, Open-Label, Retrospective, Observational Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates whether risk criteria based on MRI features could identify a cohort of patients with a good prognosis among those recommended for preoperative treatment by NCCN guidelines to avoid preoperative treatment with the likely good survival outcomes by primary surgery and more accurately indicate the response to the treatment and predict prognosis after neoadjuvant treatmen than radiographic TNM staging in the patients who received neoadjuvant therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| total mesorectal excision | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- T3 Rectal cancer
- description
- Patients with T3 rectal cancer who underwent curative surgery.
- interventionNames
- Procedure: total mesorectal excision
Primary outcomes (1)
- measure
- 3-year event-free survival rate
- timeFrame
- 3 years after the surgery
Secondary outcomes (2)
- measure
- 3-year overall survival rate
- timeFrame
- 3 years after the surgery
- measure
- Local recurrence
- timeFrame
- 3 years after the surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Underwent primary rectal adenocarcinoma resection 2. Received MRI scan before surgery 3. Willing and able to provide written informed consent for participation in this study. 4. Treatment-naive patients with histological or cytological documentation of rectal adenocarcinoma (\<12 cm from the anal verge). 5. Clinical stage of T3Nx or T1-3N+ at initial diagnosis 6. Non-complicated primary tumor (complete obstruction, perforation, bleeding). 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: 1. Treated with transanal local excision 2. with distant metastases at the time of initial diagnosis 3. Subjects with a history of a prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer. 4. Subjects with a history of any arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), myocardial infarction (MI), Transient Ischemic Attacks (TIA), or cerebralvascular accident (CVA).
References
Publications (0)
Data not yet available